Thursday, October 29, 2026

Stage 3 lung cancer patients over 70 can receive “active treatment” so “should not give up”

A study shows elderly patients (70+) with stage 3 lung cancer can complete standard treatment, challenging age-related treatment hesitance.

ABL209: The Promising Dual Antibody ADC Revolutionizing Cancer Treatment in 2026

ABL Bio's ABL209 shows promising anti-cancer effects with broad safety in preclinical studies, advancing to Phase 1 trials in the U.S.

Chang Hyun Jung

No posts to display

Top News

- Our Sponsors Ad -

Follow us